Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers

COVID-19 (coronavirus disease 2019) vaccines induce immunity through different mechanisms. The aim of this study is to compare the titers of specific antibodies in subjects vaccinated with either the Pfizer-BioNTech COVID-19 vaccine or the Sinopharm vaccine. This prospective observational cohort inc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rami Alqassieh, Aiman Suleiman, Sami Abu-Halaweh, Abeer Santarisi, Omar Shatnawi, Lara Shdaifat, Amjed Tarifi, Mohammad Al-Tamimi, Abdel-Ellah Al-Shudifat, Heba Alsmadi, Ahmed Al Sharqawi, Hadeel Alnawaiseh, Yara Anasweh, Farah Abo Domaidah, Haneen Abu Jaber, Mohammad Rashid Al-Zarir, Isam Bsisu
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	COVID-19 vaccine Pfizer-BioNTech Sinopharm antibody titers Medicine R
Acceso en línea:	https://doaj.org/article/f8f682652ba740478ffafd39c31b17c7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f8f682652ba740478ffafd39c31b17c7
record_format	dspace
spelling	oai:doaj.org-article:f8f682652ba740478ffafd39c31b17c72021-11-25T19:10:11ZPfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers10.3390/vaccines91112232076-393Xhttps://doaj.org/article/f8f682652ba740478ffafd39c31b17c72021-10-01T00:00:00Zhttps://www.mdpi.com/2076-393X/9/11/1223https://doaj.org/toc/2076-393XCOVID-19 (coronavirus disease 2019) vaccines induce immunity through different mechanisms. The aim of this study is to compare the titers of specific antibodies in subjects vaccinated with either the Pfizer-BioNTech COVID-19 vaccine or the Sinopharm vaccine. This prospective observational cohort included Jordanian adults vaccinated with two doses, 21 days apart, of either of the two aforementioned vaccines. Titers were collected 6 weeks after the administration of the second dose. Overall, 288 participants were included, of which 141 were administered the Pfizer-BioNTech vaccine, while 147 were administered the Sinopharm vaccine. Remarkably, 140 (99.3%) of the Pfizer-BioNTech vaccine recipients had positive IgG titers, while 126 (85.7%) of Sinopharm recipients had positive IgG (<i>p</i> < 0.001). The mean titer for IgG among Pfizer-BioNTech recipients was 515.5 ± 1143.5 BAU/mL, compared to 170.0 ± 230.0 BAU/mL among Sinopharm subjects (<i>p</i> < 0.001). Multivariable regression analysis showed that the Pfizer-BioNTech vaccine positively correlated with positive IgG titers (OR: 25.25; 95% CI: 3.25–196.15; <i>p</i> = 0.002), compared with a negative effect of cardiovascular diseases (OR: 0.33; 95% CI: 0.11–0.99; <i>p</i> = 0.48) on IgG titers. In conclusion, fully vaccinated recipients of the Pfizer-BioNTech vaccine had superior quantitative efficiency compared to Sinopharm recipients. A booster dose is supported for Sinopharm recipients, or those with chronic immunosuppressive diseases.Rami AlqassiehAiman SuleimanSami Abu-HalawehAbeer SantarisiOmar ShatnawiLara ShdaifatAmjed TarifiMohammad Al-TamimiAbdel-Ellah Al-ShudifatHeba AlsmadiAhmed Al SharqawiHadeel AlnawaisehYara AnaswehFarah Abo DomaidahHaneen Abu JaberMohammad Rashid Al-ZarirIsam BsisuMDPI AGarticleCOVID-19vaccinePfizer-BioNTechSinopharmantibodytitersMedicineRENVaccines, Vol 9, Iss 1223, p 1223 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	COVID-19 vaccine Pfizer-BioNTech Sinopharm antibody titers Medicine R
spellingShingle	COVID-19 vaccine Pfizer-BioNTech Sinopharm antibody titers Medicine R Rami Alqassieh Aiman Suleiman Sami Abu-Halaweh Abeer Santarisi Omar Shatnawi Lara Shdaifat Amjed Tarifi Mohammad Al-Tamimi Abdel-Ellah Al-Shudifat Heba Alsmadi Ahmed Al Sharqawi Hadeel Alnawaiseh Yara Anasweh Farah Abo Domaidah Haneen Abu Jaber Mohammad Rashid Al-Zarir Isam Bsisu Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers
description	COVID-19 (coronavirus disease 2019) vaccines induce immunity through different mechanisms. The aim of this study is to compare the titers of specific antibodies in subjects vaccinated with either the Pfizer-BioNTech COVID-19 vaccine or the Sinopharm vaccine. This prospective observational cohort included Jordanian adults vaccinated with two doses, 21 days apart, of either of the two aforementioned vaccines. Titers were collected 6 weeks after the administration of the second dose. Overall, 288 participants were included, of which 141 were administered the Pfizer-BioNTech vaccine, while 147 were administered the Sinopharm vaccine. Remarkably, 140 (99.3%) of the Pfizer-BioNTech vaccine recipients had positive IgG titers, while 126 (85.7%) of Sinopharm recipients had positive IgG (<i>p</i> < 0.001). The mean titer for IgG among Pfizer-BioNTech recipients was 515.5 ± 1143.5 BAU/mL, compared to 170.0 ± 230.0 BAU/mL among Sinopharm subjects (<i>p</i> < 0.001). Multivariable regression analysis showed that the Pfizer-BioNTech vaccine positively correlated with positive IgG titers (OR: 25.25; 95% CI: 3.25–196.15; <i>p</i> = 0.002), compared with a negative effect of cardiovascular diseases (OR: 0.33; 95% CI: 0.11–0.99; <i>p</i> = 0.48) on IgG titers. In conclusion, fully vaccinated recipients of the Pfizer-BioNTech vaccine had superior quantitative efficiency compared to Sinopharm recipients. A booster dose is supported for Sinopharm recipients, or those with chronic immunosuppressive diseases.
format	article
author	Rami Alqassieh Aiman Suleiman Sami Abu-Halaweh Abeer Santarisi Omar Shatnawi Lara Shdaifat Amjed Tarifi Mohammad Al-Tamimi Abdel-Ellah Al-Shudifat Heba Alsmadi Ahmed Al Sharqawi Hadeel Alnawaiseh Yara Anasweh Farah Abo Domaidah Haneen Abu Jaber Mohammad Rashid Al-Zarir Isam Bsisu
author_facet	Rami Alqassieh Aiman Suleiman Sami Abu-Halaweh Abeer Santarisi Omar Shatnawi Lara Shdaifat Amjed Tarifi Mohammad Al-Tamimi Abdel-Ellah Al-Shudifat Heba Alsmadi Ahmed Al Sharqawi Hadeel Alnawaiseh Yara Anasweh Farah Abo Domaidah Haneen Abu Jaber Mohammad Rashid Al-Zarir Isam Bsisu
author_sort	Rami Alqassieh
title	Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers
title_short	Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers
title_full	Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers
title_fullStr	Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers
title_full_unstemmed	Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers
title_sort	pfizer-biontech and sinopharm: a comparative study on post-vaccination antibody titers
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/f8f682652ba740478ffafd39c31b17c7
work_keys_str_mv	AT ramialqassieh pfizerbiontechandsinopharmacomparativestudyonpostvaccinationantibodytiters AT aimansuleiman pfizerbiontechandsinopharmacomparativestudyonpostvaccinationantibodytiters AT samiabuhalaweh pfizerbiontechandsinopharmacomparativestudyonpostvaccinationantibodytiters AT abeersantarisi pfizerbiontechandsinopharmacomparativestudyonpostvaccinationantibodytiters AT omarshatnawi pfizerbiontechandsinopharmacomparativestudyonpostvaccinationantibodytiters AT larashdaifat pfizerbiontechandsinopharmacomparativestudyonpostvaccinationantibodytiters AT amjedtarifi pfizerbiontechandsinopharmacomparativestudyonpostvaccinationantibodytiters AT mohammadaltamimi pfizerbiontechandsinopharmacomparativestudyonpostvaccinationantibodytiters AT abdelellahalshudifat pfizerbiontechandsinopharmacomparativestudyonpostvaccinationantibodytiters AT hebaalsmadi pfizerbiontechandsinopharmacomparativestudyonpostvaccinationantibodytiters AT ahmedalsharqawi pfizerbiontechandsinopharmacomparativestudyonpostvaccinationantibodytiters AT hadeelalnawaiseh pfizerbiontechandsinopharmacomparativestudyonpostvaccinationantibodytiters AT yaraanasweh pfizerbiontechandsinopharmacomparativestudyonpostvaccinationantibodytiters AT farahabodomaidah pfizerbiontechandsinopharmacomparativestudyonpostvaccinationantibodytiters AT haneenabujaber pfizerbiontechandsinopharmacomparativestudyonpostvaccinationantibodytiters AT mohammadrashidalzarir pfizerbiontechandsinopharmacomparativestudyonpostvaccinationantibodytiters AT isambsisu pfizerbiontechandsinopharmacomparativestudyonpostvaccinationantibodytiters
_version_	1718410255481700352

Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers

Ejemplares similares